A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 388-393

  Scribner Jr , Dennis R ^a   Puls, Larry E ^b   Gold, Michael A ^c  

^a CARILION CLINIC   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Chemotherapy; Uterine cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL;

ACUTE HEART INFARCTION; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BLURRED VISION; BODY PAIN; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; COLON PERFORATION; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPRESSION; DIARRHEA; DIVERTICULITIS; DROWSINESS; DRUG ERUPTION; DRY SKIN; DYSPHAGIA; DYSPNEA; DYSURIA; EDEMA; ENDOMETRIUM CANCER; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMATOMA; HEMATURIA; HEMORRHOID; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INDIGESTION; INSOMNIA; MAJOR CLINICAL STUDY; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; OTALGIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION FIELD; RESPIRATORY FAILURE; RESTLESS LEGS SYNDROME; SIDE EFFECT; SORE THROAT; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VAGINA DISCHARGE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 84859597678     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.02.003     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer sstatitstics. CA Cancer J Clin 2010;60: 277-300.
2. Ayhan A, Taskiran C, Celik C, Aksu T, Yuce K. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. Eur J Gynaecol Oncol 2002;23:553-6. (Pubitemid 36070003)
3. McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analuysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol 2001;81:273-8. (Pubitemid 32424174)
4. Faught W, Fung MFK, Krepart GV, Lotocki RJ, Heywood MS, Genest P. Microscopic surgical stage IIIc endometrial adenocarcinoma of the endometrium: implications for bimodal adjuvant therapy. Int J Gynecol Cancer 1998;8:41-5. (Pubitemid 28119956)
5. Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller Jr AF. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol 1996;63:34-9. (Pubitemid 26337962)
6. Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcdinoma. Prognostic factors and patterns of recurrence. Cancer 1993;71: 3697-702.
7. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
8. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Millder DS. Prognostic factors associated with recurrence in clinical stage I adenocarinoma of the endometrium. Obstet Gynecol 1991;78:63-9.
9. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 1987;60:2035-41.
10. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4.
11. Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIc endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables and failure patters following radiation therapy. Gynecol Oncol 1999;75:211-4. (Pubitemid 29523020)
12. Smith RS, Kapp DS, Chen Q, Teng NNII. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys 2000;48: 767-78.
13. Polyzos NP, Pavlidis N, Paraskevaidis E, Ioannidis JP. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer 2006;42:319-26. (Pubitemid 43132886)
14. Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997;75:1836-41. (Pubitemid 27230713)
15. Goff BA, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237-40. (Pubitemid 24064377)
16. Randall ME, Filiaci VL, Muss H, spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36-44. (Pubitemid 46630491)
17. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:2159-66. (Pubitemid 41095150)
18. Nomura H, Aoki D, Takahashi F, Kabsumorta N, Watanabe Y, Konish I, et al. Randomized phase II study comparing docetaxel and cisplatin, docitaxel and carboplatin and paclitaxel and carboplatin in patients with advanced or recurrent endometrial cancer. JGOG 2041. Ann Oncol 2011;22:636-42.
19. Pectasides d, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 2008;109:250-4.
20. Sorbe B, andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel long term follow-up. Int J Gynecol Cancer 2008;18:803-8. (Pubitemid 352020182)
21. Hoskins PJ, LeN, Ellard S, Lee U, martin LA, Swenerton KD, et al. British Columbia Cancer Agency. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant Mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 2008;108:58-62.
22. Secord AA, Havrilesky LJ, Carney ME, soper JT, Clarke-Pearson DL, Rodriguez GC, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 2007;12:31-6. (Pubitemid 46472550)
23. Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007;17:197-203. (Pubitemid 46213991)
24. Arimoto T, Nakagawa S, Yasugi T, Yoshikawa H, Kawana K, Yano T, et al. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma. Gynecol Oncol 2007;104:32-5. (Pubitemid 46054110)
25. Michener CM, Peterson G, Kulp B, Webster KD, Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 2005;131:581-4. (Pubitemid 41558550)
26. Akran T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005;192:1365-7.
27. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112:543-52.
28. Geller MA, Ivy JJ, Ghebre R, Downs Jr LS, Judson PL, Carson LF, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "sandwich" method for stage III, IV and recurrent endometrial cancer. Gynecol Oncol 2011;121:112-7.
29. Katsumarta N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer 2005;93:999-1004. (Pubitemid 41548393)
30. Gunthert AR, Ackermann S, Beckmann MW, Camera O, Kiesel L, Rensingn K, et al. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus - 4. Gynecol Oncol 2007;104:86-90. (Pubitemid 46054126)
31. Garcia AA, Blessing JA, Nolte S, Mannel RS. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: Gynecologic Oncology Group Study. Gynecol Oncol 2008;111:22-6.
32. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009;105:103-4.